ARCT-032 not checked

Arcturus Therapeutics, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Cystic Fibrosis, CFTR Gene Mutation
Main trialPhase 2
“ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.”In the company’s words, NCT06747858 on ClinicalTrials.gov

Other drugs for Cystic Fibrosis

All 16 drugs for Cystic Fibrosis

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Jun 2027 Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
Phase 1Completed 29 Jul 2024 Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ARCT-032

Following is part of Solo: you see every change to ARCT-032 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in